How long does a healthcare technology company work with a fractional Chief Revenue Officer?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Buying Committee and Deal Dynamics in Healthcare Technology

The buying committee in healthcare technology is a fractured coalition of eight to fourteen stakeholders, each with a veto and a different definition of value. For a company selling a clinical decision support tool to a multi-hospital system, the committee includes a Chief Medical Information Officer who evaluates whether the tool integrates with the existing clinical workflow without adding clicks, a Director of Quality who demands evidence of reduced adverse events or readmission rates, a Vice President of Supply Chain who questions whether the tool replaces a current vendor contract, a Chief Information Security Officer who requires a completed HITRUST assessment and a signed business associate agreement before any data exchange, and a Chief Financial Officer who requests a five-year total cost of ownership model that accounts for implementation, training, and ongoing IT support. Deal sizes range from $75,000 to $400,000 in annual contract value for a SaaS tool deployed in a single department, but can reach $1.5 million for an enterprise license covering multiple hospitals across a health system. Budget approval is a multi-layered process: the clinical department funds a pilot from its operational budget (typically $20,000 to $50,000), but the full deployment requires capital expenditure approval from the health system's finance committee, which meets quarterly and demands a formal business case with projected ROI in reduced length of stay or increased billing accuracy. Buyers evaluate not just features but the vendor's willingness to sign a data protection addendum that indemnifies the health system against breaches caused by the vendor's software, and they require references from peer institutions with similar EHR platforms and bed counts. Deals stall most often at the data security review stage, where the health system's IT security team demands a full penetration test and a review of the vendor's SOC 2 Type II report, a process that takes 60 to 120 days and cannot be accelerated because the security team is understaffed and prioritizes internal projects over vendor reviews.

Sales-Cycle Implications: The Motion, Ramp, and Pipeline Shape

The sales cycle in healthcare technology is not a linear pipeline but a series of sequential gates, each requiring a different sales motion. The fractional CRO must first execute a "clinical discovery" phase where they identify the specific clinical problem the tool solves and quantify its impact in terms of time saved or errors reduced, then a "technical validation" phase where the IT team runs a proof of concept that tests integration with the health system's instance of Epic or Cerner, and finally a "procurement" phase where the vendor's legal team negotiates the business associate agreement and the health system's finance team approves the budget. Ramp time for a new fractional leader is 75 to 100 days, but only if they inherit a CRM with complete call logs and deal histories; if the company has no CRM or uses a spreadsheet, ramp extends to 130 days because the fractional leader must interview every past prospect and reconstruct the buyer's journey from scratch. Forecast behavior is unreliable until month 8 because healthcare deals have a 25% to 35% probability of closing even when the champion has verbally committed, due to unexpected budget freezes when the health system misses its quarterly earnings target or when a new regulatory requirement like CMS's Interoperability Rule diverts IT resources. The pipeline shape is a reverse funnel: many early-stage leads from conferences like HIMSS or the American Telemedicine Association convert to pilot discussions, but only 8% to 12% reach the legal stage, and the final close rate from legal to signed contract is 45% to 55% because the health system's legal team adds new requirements like a data retention clause or a limitation of liability that the vendor cannot accept. Leaks are concentrated at three points: first, the "champion departure" where the clinical advocate who drove the pilot leaves the health system and the new department head has no loyalty to the vendor; second, the "budget reallocation" where the health system diverts funds to an EHR upgrade or a new regulatory mandate; third, the "procurement fatigue" where the vendor's legal team cannot keep up with the health system's redlines and the deal dies from neglect. The fractional CRO must build a pipeline that is 4 to 5 times the revenue target to account for these leaks, and they must maintain a "regulatory watch" list of deals that are paused due to pending CMS rule changes or FDA decisions, requiring monthly check-ins rather than weekly pushes.

What a Fractional Chief Revenue Officer Looks Like Here: First 90 Days, Cadence, and Ownership

The first 90 days for a fractional CRO in healthcare technology is a forensic audit of the company's clinical credibility and sales infrastructure. In days 1 to 30, they audit the existing sales process and team composition, but they also conduct 25 to 35 discovery calls with lost prospects and current customers to map the exact clinical workflow the tool supports and identify why deals died at the data security review or procurement stages. In days 31 to 60, they re-engineer the sales playbook to include clinical outcome scripts (e.g., "Our tool reduced door-to-needle time by 12 minutes at a similar academic medical center") and technical qualification criteria (e.g., "Does your EHR support HL7 FHIR version 4?"), and they implement a deal review cadence with weekly pipeline meetings that force reps to update probability based on specific milestones like "pilot completed" or "business associate agreement signed." In days 61 to 90, they set a 12-month revenue target with a monthly phasing plan that accounts for the health system's fiscal year calendar (most health systems have budgets locked from October to September), install a forecasting methodology using weighted pipeline with separate probabilities for clinical validation, technical validation, and procurement stages, and initiate a hiring plan for one or two enterprise account executives who have existing relationships with health system IT directors in the target geography. Their operating cadence is intensive: they work 25 to 35 hours per week, with three core days on-site or in virtual meetings with the CEO and board, plus two days for asynchronous work like reviewing security questionnaires and redlining business associate agreements. They own the full revenue function, including sales, customer success, and marketing, but they advise on product pricing and regulatory strategy rather than owning those directly. They do not run day-to-day sales calls except for top-tier enterprise prospects where their credibility with health system C-suite buyers is essential, and they attend two to three industry conferences per year to build relationships with key opinion leaders who can provide references. The signals to convert to full-time are clear: when the company hits $8 million to $12 million in ARR, the fractional role becomes unsustainable because the complexity of managing a 10-person sales team, a 5-person customer success team, and a marketing budget requires a leader who is available 50 to 60 hours per week, not 25 to 35. Other signals include when the company raises a Series B round and the board demands a full-time executive for governance reasons, or when the company enters a new clinical vertical (e.g., expanding from emergency department to intensive care unit) that requires a dedicated leader to build a separate sales motion with a different buyer committee. If the company fails to hit $4 million ARR after 18 months, the fractional CRO is often not converted but replaced with a different fractional leader who has a different skill set, such as one focused on channel partnerships with group purchasing organizations like Vizient or Premier.

The Fractional CRO's Role in Clinical Validation and Evidence Generation

A healthcare technology fractional CRO must act as a bridge between the sales team and the company's clinical advisory board, ensuring that every sales conversation is grounded in peer-reviewed evidence or pilot data. They must work with the company's chief medical officer to develop a "clinical evidence dossier" that includes case studies, white papers, and abstracts from relevant medical journals, and they must train reps to answer questions about the tool's sensitivity and specificity, positive predictive value, and number needed to treat. The fractional leader often negotiates with health system research departments to run a formal clinical study that generates the evidence needed to close enterprise deals, a process that takes 6 to 12 months and requires the fractional CRO to allocate 10% to 15% of their weekly time to study design and site selection. A key buying dynamic here is that the health system's chief medical officer will not approve a tool without published evidence in a peer-reviewed journal, and the fractional CRO must build a relationship with that officer early by offering a complimentary pilot with a data-sharing agreement that allows the vendor to publish the results. The implication for the sales cycle is that the fractional CRO must maintain a separate "evidence pipeline" of studies and publications that are timed to coincide with the health system's purchasing cycle, and they must prioritize deals where the health system has a research arm that can co-author a study.

The Economics of the Engagement: Retainer, Equity, and Exit Triggers

The fractional CRO engagement is structured as a monthly retainer of $18,000 to $35,000 for 25 to 35 hours per week, plus a performance bonus of 1.5% to 3.5% of incremental revenue above a baseline, and often a small equity grant (0.75% to 1.5% of the company) that vests over 24 months with a one-year cliff. The retainer covers the diagnostic phase and ongoing management, while the bonus aligns the fractional leader with growth outcomes and compensates for the uncertainty of healthcare sales cycles. The equity grant is a retention tool that discourages the fractional CRO from leaving before the 14-month mark, but it also creates a conversion trigger: if the company raises a Series A or B round, the board often insists on converting the fractional role to full-time to avoid the optics of a part-time executive with equity and to ensure the leader is fully committed during the post-funding growth phase. The exit trigger is not just revenue but also operational maturity: when the company has a repeatable sales process, a trained team of 5 to 7 reps who can independently navigate the health system's buying committee, and a CRM that is used consistently with accurate probability updates, the fractional CRO's value diminishes because the job becomes execution rather than architecture. The company typically gives a 45 to 60 day notice when they decide to hire a full-time CRO, and the fractional leader often stays for a 45-day handoff period to train the successor and introduce them to key buyer relationships at health systems that are in the middle of a procurement cycle.

The Geographic and Market-Specific Constraints

Healthcare technology companies are concentrated in specific regions - Boston, Silicon Valley, Nashville, Minneapolis, and the Research Triangle - and the fractional CRO must have existing relationships in those markets to be effective. For example, a company selling to health systems in the Midwest needs a fractional leader who knows the group purchasing organization dynamics of Premier or HealthTrust, because many deals require a GPO contract to even be considered, and the fractional leader must have a pre-existing relationship with the GPO's contracting team to accelerate the process. The fractional CRO must also understand the difference between selling to academic medical centers (longer cycles, more clinical validation required, higher deal sizes) versus community hospitals (shorter cycles, price sensitivity, reliance on GPO contracts). A common mistake is assuming a fractional CRO from a general SaaS background can adapt to healthcare, but the reality is that healthcare buyers are skeptical of outsiders, and the fractional leader must have at least 5 years of healthcare-specific experience, including a network of physician champions, IT directors, and GPO contracting officers. The implication for the engagement duration is that a fractional CRO without existing relationships in the target market will need 5 to 7 months just to build credibility, extending the engagement to 20 to 26 months minimum.

FAQ

What is the typical minimum engagement period for a fractional CRO in healthcare technology? Most engagements run at least six months to allow time for assessment, strategy development, and initial execution. Healthcare technology sales cycles are long, so a shorter period rarely yields meaningful revenue impact.

Can a fractional CRO engagement be extended beyond the initial term? Yes, contracts are commonly renewed in three-to-six-month increments as priorities shift. Many healthcare technology companies extend to oversee the full execution of a new go-to-market plan or through a major product launch.

What factors determine whether the engagement ends early? Early exits usually happen if the company achieves its revenue milestone faster than projected or if the founder decides to hire a full-time executive. However, abrupt endings are rare because the fractional model is designed for phased handoffs.

How does the engagement typically conclude? The standard conclusion involves a structured transition to an internal revenue leader or a full-time CRO. The fractional CRO often stays on for a brief overlap period to ensure knowledge transfer and maintain pipeline momentum.

Sources